Literature DB >> 32009414

Regioselective Synthesis of a C-4'' Carbamate,C-6'' n-Pr Substituted Cyclitol Analogue of SL0101.

Yu Li1, Zachary M Sandusky2, Rajender Vemula1, Qi Zhang1, Bulan Wu3, Shinji Fukuda2,4,5, Mingzong Li1, Deborah A Lannigan2,6,7, George A O'Doherty1.   

Abstract

An asymmetric synthesis of two analogues of SL0101 (1) has been achieved. The effort is aimed at the discovery of inhibitors of the p90 ribosomal S6 kinase (RSK) with improved bioavailability. The route relies upon the use of the Taylor catalyst to regioselectively install C-3″ acetyl or carbamate functionality. This study led to the identification of a third-generation analogue of SL0101 with a C-4n-Pr-carbamate and a C-3acetate with improved RSK inhibitory activity.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32009414      PMCID: PMC7292201          DOI: 10.1021/acs.orglett.0c00042

Source DB:  PubMed          Journal:  Org Lett        ISSN: 1523-7052            Impact factor:   6.005


  32 in total

Review 1.  Circulating tumor cells in breast cancer--current status and perspectives.

Authors:  Malgorzata Banys-Paluchowski; Natalia Krawczyk; Franziska Meier-Stiegen; Tanja Fehm
Journal:  Crit Rev Oncol Hematol       Date:  2015-10-31       Impact factor: 6.312

2.  De novo asymmetric synthesis of the mezzettiaside family of natural products via the iterative use of a dual B-/Pd-catalyzed glycosylation.

Authors:  Sumit O Bajaj; Ehesan U Sharif; Novruz G Akhmedov; George A O'Doherty
Journal:  Chem Sci       Date:  2014-06       Impact factor: 9.825

3.  Synthesis of a potent and selective inhibitor of p90 Rsk.

Authors:  David J Maloney; Sidney M Hecht
Journal:  Org Lett       Date:  2005-03-17       Impact factor: 6.005

Review 4.  Rationale for targeting the Ras/MAPK pathway in triple-negative breast cancer.

Authors:  Jennifer M Giltnane; Justin M Balko
Journal:  Discov Med       Date:  2014-05       Impact factor: 2.970

Review 5.  Ribosomal S6 kinase (RSK) modulators: a patent review.

Authors:  Katarzyna A Ludwik; Deborah A Lannigan
Journal:  Expert Opin Ther Pat       Date:  2016-08-01       Impact factor: 6.674

Review 6.  Targeting RAS-ERK signalling in cancer: promises and challenges.

Authors:  Ahmed A Samatar; Poulikos I Poulikakos
Journal:  Nat Rev Drug Discov       Date:  2014-12       Impact factor: 84.694

7.  Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer.

Authors:  Katarzyna A Ludwik; J Preston Campbell; Mingzong Li; Yu Li; Zachary M Sandusky; Lejla Pasic; Miranda E Sowder; David R Brenin; Jennifer A Pietenpol; George A O'Doherty; Deborah A Lannigan
Journal:  Mol Cancer Ther       Date:  2016-08-15       Impact factor: 6.261

8.  Epidermal growth factor (EGF) regulates α5β1 integrin activation state in human cancer cell lines through the p90RSK-dependent phosphorylation of filamin A.

Authors:  Daniel Vial; Paula J McKeown-Longo
Journal:  J Biol Chem       Date:  2012-09-24       Impact factor: 5.157

9.  Synthesis of carbasugar C-1 phosphates via Pd-catalyzed cyclopropanol ring opening.

Authors:  Mingde Shan; George A O'Doherty
Journal:  Org Lett       Date:  2008-07-18       Impact factor: 6.005

10.  Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer.

Authors:  James S Duncan; Martin C Whittle; Kazuhiro Nakamura; Amy N Abell; Alicia A Midland; Jon S Zawistowski; Nancy L Johnson; Deborah A Granger; Nicole Vincent Jordan; David B Darr; Jerry Usary; Pei-Fen Kuan; David M Smalley; Ben Major; Xiaping He; Katherine A Hoadley; Bing Zhou; Norman E Sharpless; Charles M Perou; William Y Kim; Shawn M Gomez; Xin Chen; Jian Jin; Stephen V Frye; H Shelton Earp; Lee M Graves; Gary L Johnson
Journal:  Cell       Date:  2012-04-13       Impact factor: 41.582

View more
  1 in total

1.  Synthesis and Biological Evaluation of 4'-Substituted Kaempfer-3-ols.

Authors:  Sugyeom Kim; Yu Li; Lin Lin; Peyton R Sayasith; Ariel T Tarr; Eric B Wright; Sharia Yasmin; Deborah A Lannigan; George A O'Doherty
Journal:  J Org Chem       Date:  2020-02-27       Impact factor: 4.354

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.